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ABSTRACT
As molecular and cellular therapies advance in the
clinic, the role of genetic regulation is becoming in-
creasingly important for controlling therapeutic po-
tency and safety. The emerging field of mammalian
synthetic biology provides promising tools for the
construction of regulatory platforms that can inter-
vene with endogenous pathways and control cell
behavior. Recent work has highlighted the develop-
ment of synthetic biological systems that integrate
sensing of molecular signals to regulated therapeu-
tic function in various disease settings. However,
the toxicity and limited dosing of currently available
molecular inducers have largely inhibited translation
to clinical settings. In this work, we developed syn-
thetic microRNA-based genetic systems that are con-
trolled by the pharmaceutical drug leucovorin, which
is readily available and safe for prolonged adminis-
tration in clinical settings. We designed microRNA
switches to target endogenous cytokine receptor
subunits (IL-2R and c) that mediate various signal-
ing pathways in T cells. We demonstrate the function
of these control systems by effectively regulating T
cell proliferation with the drug input. Each control
system produced unique functional responses, and
combinatorial targeting of multiple receptor subunits
exhibited greater repression of cell growth. This work
highlights the potential use of drug-responsive ge-
netic control systems to improve the management
and safety of cellular therapeutics.
INTRODUCTION
The tools of synthetic biology are advancing our ability to
design, modulate, and reprogram biological activity. Pro-
grammed cells can interface with complex biological sys-
tems and introduce novel functionality that is otherwise
difficult to reproduce from nature. Recent advances in the
field have led to growing interest in genetically engineering
mammalian cells towards various applications in health and
medicine (1,2). One area that has gained significant interest
is in cell-based therapy, where cells are used as therapeutic
agents to treat diseases. Unlike small-molecule drugs, cells
have inherent therapeutic capabilities that enable them to
sense signals, localize to specific tissue environments, and
execute complex tasks (3–5). These features may potentially
be harnessed to treat a range of disorders, and indeed, revo-
lutionary clinical trials have highlighted the promise of us-
ing engineered cells as therapy (6–13).
One example that has recently gained significant atten-
tion is the use of engineered T cells as therapeutic agents.
T cells offer an attractive platform because of their innate
ability to survey the body for specific molecular signatures
and exhibit targeted cytotoxicity. They can be readily iso-
lated from the blood and genetically manipulated and ex-
panded ex vivo to generate a personalized cellular therapy.
Researchers have genetically modified T cells to redirect
their killing specificity towards cancer cells via the expres-
sion of engineered T cell receptors (14–16) and chimeric
antigen receptors (CARs) (17–19); these synthetic receptors
can significantly boost the immune response from antigen-
stimulated T cells. In particular, clinical trials with CAR
T cells have demonstrated remarkable success in treating B
cell hematological malignancies (7,8,10,12,20). T cells have
also been engineered to express therapeutic payloads (i.e.
IL-12) to enhance T cell function (21,22). The localized de-
livery of cytokines, chemokines and other immune effec-
tors may aid in boosting the immune response to overcome
the immunosuppressive environment that is characteristic
of solid tumors.
Despite the promise of engineered cells as therapy, one of
the primary concerns is the lack of control over cell behavior
and function when the cells are inside a patient. Engineered
cells can exhibit potent effector functions, and the challenge
in predicting their efficacy and response in vivo stresses the
need for strategies that can effectively intervene with and
control cell behavior. CAR T cells have shown incredible
efficacy but also severe (and in some cases fatal) toxicities
that were difficult to anticipate (14,15,23–27). Therefore,
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numerous efforts have been directed towards improving the
safety profile of geneticallymodified T cells, such as control-
ling cell death with suicide switches (28,29) and engineering
more sophisticated CARs (30–34).
As an alternative strategy, we explored the use of RNA-
based, conditional gene expression systems for modulating
T cell behavior. Synthetic RNA switches that link the de-
tection of molecular input signals to regulated gene expres-
sion events have been constructed using a variety of regu-
latory mechanisms on the levels of transcription, transla-
tion, RNA splicing, mRNA stability, and post-translational
processes (35,36). These RNA-based controllers integrate
sensing (encoded by anRNA aptamer) and gene-regulatory
functions (encoded by an RNA regulatory element) into a
compact framework. RNA control systems avoid the im-
munogenicity of protein components, and their small ge-
netic footprint facilitates translation to therapeutic appli-
cations. Since RNA aptamers can be generated de novo to
diverse molecular ligands (37), these RNA platforms offer
the potential to develop genetic control systems that are tai-
lored to sense application-specific molecular inputs. By im-
plementing small-molecule control systems in T cells, clini-
cians may administer a drug input to precisely control tim-
ing and release of therapeutic payload. In contrast to using
suicide switches, this strategy will be advantageous in tai-
loring treatment to cases of varying severities, while main-
taining T cell therapeutic activity. A recent study demon-
strated the use of small molecules to control CAR recon-
stitution and subsequent signaling (31). However, the ra-
pamycin analog used as the trigger molecule has a short
half-life that may limit its clinical applicability, and ligand-
responsive dimerization domains are difficult to reengineer
and be adapted to other input molecules.
In this work, we developed drug-responsive, microRNA
(miRNA)-based gene regulatory systems that are capable
of modulating cell proliferation in T cells. These miRNA
switches are responsive to the biologically inactive ingredi-
ent of leucovorin ((6R)-folinic acid), a pharmaceutical drug
that has ideal pharmacokinetic properties for clinical use,
thus overcoming the barriers inherent to common small
molecule-regulated genetic control systems.We constructed
various drug-responsive miRNA switch systems and ap-
plied them to regulate multiple components in the cytokine
signaling pathway. We show that these systems can effec-
tively modulate T cell proliferation in response to drug in-
put by exerting tight control over critical upstream signaling
molecules. ThemiRNA switches described in this workmay
also be adapted to target other endogenous genes and tai-
lored for therapeutic applications that require genetic con-
trol.
MATERIALS AND METHODS
Plasmids and reagents
All plasmids were constructed using standard molecular
biology cloning techniques (see Supplementary Materials
for details). DNA synthesis was performed by Integrated
DNA Technologies (Coralville, IA, USA) or the Protein
and Nucleic Acid Facility (Stanford, CA, USA). Enzymes
for cloning, including restriction enzymes, polymerases, and
ligases, were obtained fromNew England Biolabs (Ipswich,
MA, USA). All cloned constructs were sequence-verified
by Elim Biopharmaceuticals (Hayward, CA, USA). DNA
assembly was performed using Gibson cloning (NEB) and
the MultiSite Gateway Cloning System (Life Technolo-
gies) following manufacturer’s instructions. (6R)-, (6S)- and
(6R,S)-folinic acid were obtained from Schircks Laborato-
ries (Jona, Switzerland).
T cell culture maintenance
The CTLL-2 murine T cell line was obtained from ATCC
and maintained in RPMI-1640 medium (Lonza) supple-
mented with 10% heat-inactivated FBS (Hyclone), 2 mM
sodiumpyruvate (Gibco), and 4.5 g/l D-(+)-glucose (Sigma-
Aldrich). Cells were fed 100 U/ml IL-2 every 72 hours
and maintained at densities between 0.02 and 0.5 × 106
cells/ml. In addition, CTLL-2 platform lines were cultured
in 0.25 mg/ml hygromycin (Life Technologies), and stably
integrated cell lines were cultured in 0.1 mg/ml zeocin (Life
Technologies).
microRNA design
The web-based BLOCK-iT RNAi Designer tool (Thermo
Fisher Scientific) was used to identify candidate miRNA se-
quences. All miRNAs were designed to bind in the ORF or
3’ UTRwith 100% homology to their target mRNA per the
algorithm.
Plasmid DNA transfection in CTLL-2 cells
All transfections in CTLL-2 cells were performed with an
Amaxa Nucleofector II Device and the Mouse T Cell Nu-
cleofector Kit (Lonza) following manufacturer’s protocols.
The electroporations were performed using 1 × 106 cells
with 4g of total plasmidDNA (encodingmiRNA switch).
For stable integrations, the destination vector and integrase
vector were combined in a 1:1 mass ratio. Each transfected
sample was diluted 2-fold in supplemented media with IL-
2, split into the desired number of conditions, and treated
with the indicated concentration of drug input. For tran-
sient assay, the cells were harvested for antibody staining
and fluorescence quantification after 24 h. For stable inte-
grations, the cells were selected in 0.1 mg/ml zeocin (Life
Technologies).
Cell surface staining for cytokine receptor expression
Cells were harvested for cytokine receptor staining bywash-
ing each sample once with 500 l HBSS, incubating with
either 0.75 l PE-conjugated mouse IL-2R (BioLegend,
clone 5H4) or 2.5 l PE-conjugated mouse  c (BioLegend,
clone TUGm2) antibody in HBSS in a total volume of 50
l for 15 min at 4◦C in the dark, washing twice with 500 l
HBSS, and analyzing on aMACSQuant VYB flow cytome-
ter (Miltenyi Biotec). Fluorescence intensities were quanti-
fied as the geometric mean intensity observed in the gated
population. Reported expression levels represent the mean
± SD of three replicate samples.
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Generation of a clonal CTLL-2 platform line
To generate a clonal CTLL-2 platform cell line for site-
specific integration of transgenes, we used modified vectors
obtained from the Jump-In TI Gateway System (Life Tech-
nologies) and followed manufacturer’s protocols. Briefly,
the process involved: (i) creating the platform cell line, (ii)
sorting the transformants into single clones and (iii) screen-
ing the individual clonal cell lines. A transient transfection
was performed with 2 × 106 CTLL-2 cells with 10 g of
plasmid DNA (1:1 ratio of pJTI Bxb1 tTA2-Zeo and pJTI
PhiC31 Int). Twenty four hours following transfection, the
cells were placed in fresh media with IL-2 and diluted to
a total volume of 40 ml in a T75 flask, and hygromycin
(Life Technologies) was added 24 h later to a final con-
centration of 0.25 mg/ml to select for stable transformants.
The media was replenished every week thereafter, and the
cells were split as necessary to avoid overcrowding. After 3
weeks of selection and growth, the cells were stained with
a 7-AAD viability dye (Life Technologies) and sorted into
single, viable clones on a BD Influx (BD Biosciences) cell
sorter. Individual clones were sorted into 200 l of media
supplemented with IL-2 and hygromycin. The clonal popu-
lations were individually selected after >2 weeks of growth
by clonal expansion and viability, and the successfully ex-
panded clones were individually screened by stably integrat-
ing a GFP reporter (pJTI pTet-GFP) using the Bxb1 in-
tegrase (pCMV-Bx). Screening was necessary to determine
the level of gene expression at the integration loci. We se-
lected a clone that displayed stable, robust and inducible ex-
pression of GFP over time.
Growth assays
Cells were harvested, washed twice with HBSS, and seeded
at 0.025 × 106 cells/ml in the absence or presence of 100
U/ml IL-2 (depending on whether or not the cells stably
expressed the IL-15 proliferative cytokine). (6R)-FA was
added to the indicated concentrations, and the cultures were
sequentially expanded over time into largermediums as nec-
essary. Cell count was obtained by assaying 50l of cell cul-
ture on a Quanta Cell Lab flow cytometer (Beckman Coul-
ter). Total cell count was calculated by the formula:
total cell count = number of viable cells detected
volume analyzed
× total volume of culture
× dilution
where dilution indicates the split ratio when expanding
into a larger medium. Reported total cell counts represent
the mean ± SD of three replicate samples. For the 24-day
growth experiment assaying response to drug input avail-
ability, cells were washed twice with HBSS on day 12, split
into two equal volumes, and reseeded at 0.05× 106 cells/ml.
(6R)-FA was added to one of the two volumes, and water
was added to the other.
Cell surface staining for CD19 expression
CD19 staining was performed by washing 0.5 × 106 cells
once with 500 l HBSS (Gibco), incubating with 5 l PE-
conjugated CD19 antibody (Beckman Coulter) in HBSS in
a total volume of 25 l for 15 min at 4◦C in the dark, wash-
ing twice with 500 l HBSS, and analyzing on a MAC-
SQuant VYB flow cytometer (Miltenyi Biotec).
ELISA analysis of IL-15 levels
Cells were seeded at 0.01 × 106 cells/ml in T25 flasks. After
5 days, the cell culture supernatant was collected for IL-15
measurement using the Human IL-15 Quantikine ELISA
Kit (R&D Systems) following manufacturer’s protocols.
The absorbance was measured at 450 nm (reference set at
540 nm) using a Tecan Safire Microplate Reader (Tecan).
A standard curve (constructed from standards provided in
the kit) was used to determine the concentration of IL-15.
Reported concentrations represent the mean ± SD of three
replicate samples.
Statistical analysis
Reported gene-regulatory activities represent the mean ±
SD of at least two replicate samples (n = 2 or n = 3). Cell
count measurements represent mean ± SD of three repli-
cate samples (unless otherwise indicated). Statistical signifi-
cance was calculated using Student’s t-test and indicated by
asterisks (n = 3; **P < 0.01).
RESULTS
Identification of a clinically applicable, small-molecule drug
for regulating RNA switches
A major barrier to the translation of RNA-based con-
trollers into therapeutic applications is the lack of synthetic
RNA switches that sense clinically suitable, small-molecule
ligands. The theophylline aptamer has been the model ap-
tamer of choice for mammalian cell applications that in-
volve small-molecule regulation (38,39), but the toxicity and
narrow therapeutic index of theophylline limit its practical
use in physiological settings. We therefore focused our at-
tention on designing RNA switches that respond to a clin-
ically relevant input molecule, such as the pharmaceutical
drug folinic acid (FA), a commonly used adjuvant in cancer
chemotherapy (40,41). FA has been previously approved for
clinical administration by the U.S. FDA as a racemic form
((6R,S)-FA; known as leucovorin) or as the single diastere-
omer ((6S)-FA; known as levoleucovorin). (6S)-FA is natu-
rally occurring and biologically active, but the (6R)-FA di-
astereomer is heterologous and not biologically active (Fig-
ure 1A). Pharmacokinetic studies have shown that (6R)-FA
is metabolized slower and has a significantly longer plasma
half-life than that of (6S)-FA (42). We performed a toxic-
ity study of (6R)-FA to verify that it is nontoxic at concen-
trations used for regulating RNA switch activity (Supple-
mentary Figure S1A). This combination of low toxicity, bi-
ological stability, and absence in natural physiological en-
vironments make (6R)-FA an ideal input signal for small
molecule-regulated control systems.
Several RNA aptamers to (6R)-FA have been previously
generated using in vitro selection strategies (43). These ap-
tamers have dissociation constants <400 nM at physiolog-
ically relevant Mg2+ concentrations (0.5 mM) and ligand
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Figure 1. Rational design of a (6R)-FA-responsive miRNA switch to regulate endogenous genes. (A) Chemical structures of (6S)-FA (biologically active)
and (6R)-FA (biologically inactive). (B) Predicted secondary structure of the FAt8-3 aptamer. The equilibrium dissociation constants (Kd) to (6R)-FA and
(6S)-FA were measured using surface plasmon resonance and represent the mean and standard deviation of three independent experiments. (C) Schematic
representation of miRNA switch design. An IL-2R-targeting miRNA switch was constructed by integrating the FAt8-3 aptamer into the basal segment
domain of an IL-2R-targeting miRNA. In the upright orientation, stems I and III of FAt8-3 are aligned towards the terminal loop and basal segment
of the miRNA, respectively. In the rotated orientation, stems I and III of FAt8-3 are aligned towards the basal segment and terminal loop of the miRNA,
respectively. Blue, aptamer; black, miRNA. (D) Panel of miRNA switch designs. For each aptamer orientation (upright or rotated), a panel of switch
designs were constructed with subtle structural modifications in the bulge loop size and nucleotide positioning. Switch designs with a rotated aptamer
orientation contain two bulge loops, and the indicated size represents the top bulge loop. In selected designs, specific base pairs above the bulge loop were
mutated to create an extra bulge. See Supplementary Figure S2 for the predicted secondary structures. (E) Gene-regulatory activities of the miRNA switch
panel analyzed by transient transfection in CTLL-2 cells. IL-2R expression levels were examined by cell surface staining in the absence and presence of
(6R)-FA, and the mean fluorescence intensity was normalized to those of cells transfected with a construct that lacks a miRNA switch. -miR represents
an IL-2R-targeting miRNA that lacks an aptamer. (F) Predicted secondary structure of -FAmiR12. IL-2R-targeting sequence is highlighted in red.
The nucleotide highlighted in cyan represents a modification to the original FAt-8-3 aptamer bulge loop. (G) Multiple-copy miRNA expression improves
gene-regulatory activity of -FAmiR12. -FAmiR12 incorporates a modified FAt8-3 aptamer in the basal segment domain of -miR. IL-2R expression
was examined as described in (E). Reported IL-2R expression represents mean ± SD from two replicate samples.
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specificities up to three orders of magnitude higher than
those of structurally similar molecules. Based on the indi-
vidual structure and sequence flexibility of these aptamers,
we chose the FAt8-3 aptamer as the sensor for designing an
RNA switch (Figure 1B and Supplementary Figure S1B).
Design of a (6R)-FA-responsive microRNA switch to target
endogenous genes
MicroRNAs (miRNAs) are a type of small noncoding
RNA that mediates sequence-specific, post-transcriptional
gene silencing through the RNAi pathway. The ability of
miRNAs to silence endogenous genes offers a potential
regulatory mechanism for the modulation of key signal-
ing molecules that affect T cell growth. Previous work
has demonstrated the construction of ligand-responsive
miRNA switches by integrating an RNA aptamer into
the basal segment of a miRNA hairpin to confer ligand-
responsive activity (44). Ligand binding to the aptamer in-
hibits proper maturation of the miRNA, thereby leading to
a reduction in RNAi-mediated gene silencing and a subse-
quent increase in target gene expression. However, the pre-
viousmiRNAswitcheswere designed using the theophylline
aptamer, which contains a relatively compact 15 nucleotide
(nt) core binding site (45). In contrast, the FAt8-3 aptamer
contains a single 13 nt bulge loop enclosed by 3 stem loops.
Given the dissimilar structures of the two aptamers, we cre-
ated new miRNA switch designs to support integration of
the FAt8-3 aptamer.
We rationally designed a (6R)-FA-responsive miRNA
switch by integrating the FAt8-3 aptamer into the basal seg-
ment domain of an IL-2R-targeting miRNA (Figure 1C).
IL-2R is a cytokine receptor that is displayed on the sur-
face of T cells, and we used IL-2R expression as the tran-
sient readout to assay miRNA activity in CTLL-2 cells (an
IL-2-dependent murine T cell line). We used stems I and III
of FAt8-3 as points for integration into a miRNA hairpin
that encodes an IL-2R-targeting miRNA sequence (iden-
tified through screening). The upright orientation involves
aligning stem I towards the terminal loop and stem III to-
wards the basal segment of the miRNA, and the rotated
orientation exhibits the reverse alignment. Previous studies
have shown that gene-silencing activity is highly sensitive
to the structure of the miRNA, and a sufficient bulge size in
themiRNAbasal segment region is required for proper pro-
cessing by ribonucleases (46). Therefore, we made a panel
of switch designs for each orientation containing various
structural alterations in the basal segments of the miRNA
switch (Figure 1D and Supplementary Figure S2). To exam-
ine gene-regulatory activity, we performed transient trans-
fection assays in CTLL-2 cells and measured IL-2R ex-
pression via surface antibody staining in the presence and
absence of (6R)-FA (Figure 1E).
Characterization data of initial switch designs containing
the unmodified FAt8-3 aptamer confirms the importance of
a sufficient bulge loop size. In particular, -FAmiR3 exhib-
ited a loss of knockdown activity when FAt8-3 was inte-
grated in the basal segment region of -miR (an IL-2R-
targeting miRNA), hence suggesting that the 13 nt bulge
loop in FAt8-3 was insufficient to render proper matura-
tion of the miRNA in vivo. Therefore, we made subtle struc-
tural modifications by truncating the aptamer domain and
increasing the bulge loop size to facilitate Drosha process-
ing of the miRNA (44). We examined 14 and 15 nt bulge
loop sizes by adding nucleotides to various positions within
the bulge loop.We alsomutated specific base pairs above the
bulge loop to create a small bulge to decrease the structural
rigidity of the miRNA hairpin. However, extensive modi-
fications of FAt8-3 abolished sensitivity of the aptamer to
(6R)-FA, so we introduced subtle changes to determine the
design space that afforded a balance between gene-silencing
activity and ligand responsiveness.
The majority of switch designs in the panel either lost
gene-silencing activity or exhibited minimal responsive-
ness to (6R)-FA. In the rotated orientation, three of five
switch designs retained gene-silencing activity, but only -
FAmiR18 exhibited a response to (6R)-FA (18% increase
in gene expression). In the upright orientation, most of
the switch designs lost gene-silencing activity, likely due to
an insufficient bulge loop size. However, -FAmiR12 ex-
hibited an optimal combination of gene-silencing activity
(20% knockdown) and responsiveness to input (17% in-
crease in gene expression). -FAmiR12 contains a trun-
cated and modified FAt8-3 aptamer, where an extra C is
placed in the region between stems II and III of FAt8-3
(Figure 1F). Multiple-copy miRNA expression led to in-
creased gene silencing (57% knockdown) and improved dy-
namic range (35% difference in gene expression between
the presence and absence of drug input) (Figure 1G). Bind-
ing assays via surface plasmon resonance confirmed that
-FAmiR12 exhibits a similar binding affinity for (6R)-FA
compared to that of the unmodified FAt8-3 aptamer (Sup-
plementary Figure S3). Based on the gene-silencing and reg-
ulatory activities, we selected -FAmiR12 as the optimal
miRNA switch design for regulating endogenous gene ex-
pression in response to (6R)-FA.
(6R)-FA-responsive miRNA switches exhibit regulation of cy-
tokine receptor expression
Cytokines often share receptor subunits and can mediate
functionally overlapping immune responses. For example,
IL-2 and IL-15 both utilize IL-2R (CD122) and the com-
mon  chain ( c; also known as CD132) as signaling sub-
units in their respective heterotrimeric receptors (47). IL-2
and IL-15 can thus mediate common intracellular signal-
ing pathways leading to T cell activation and proliferation
(48). In addition,  c also confers responsiveness to other
cytokines such as IL-4, IL-7, IL-9 and IL-21. The promis-
cuous roles played by IL-2R and  c in T cell signaling
indicate that they may be effective targets for regulation.
Moreover, since receptor subunits control upstream signal-
ing events, their regulatory effects may be further amplified
by downstream signaling cascades.
Using our optimized switch design, we also constructed
miRNA switches to target the  c cytokine receptor subunit,
which is critical for mediating T cell proliferation. Overall,
we identified IL-2R- and  c-targeting miRNA sequences
that show effective silencing of their intended target recep-
tor with high specificity (Supplementary Figure S4). To as-
sess the regulatory effects on cytokine receptor expression,
we generated T cell lines stably expressing various (6R)-FA-
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Figure 2. IL-2R- and  c-targeting miRNA switches exhibit drug-mediated control of gene silencing. (A) Schematic representation of the miRNA switch
system stably integrated in CTLL-2 cells. The miRNA switches were encoded in the 3’ UTR of a GFP reporter and target endogenously expressed IL-2R
and/or  c, which form part of the heterotrimeric IL-2 receptor. miRNA maturation results in formation of mature miRNA and subsequent degradation
of the mRNA transcript. Exogenous IL-2 was fed to the cells. Blue, aptamer; black, miRNA; ‘x’, miRNA switch copy number; IL-2R, IL-2 receptor.
(B) (6R)-FA-mediated regulation of IL-2R and  c cytokine receptor expression. Clonal cell lines harboring the indicated miRNA switch systems were
treated with the specified concentrations of (6R)-FA. IL-2R and  c expression were examined by cell surface staining, and the mean fluorescence intensity
was normalized to those of cells harboring a non-targeting miRNA switch. See Supplementary Figure S6 for representative flow cytometry histograms.
Reported IL-2R and  c expression represent mean ± SD from three replicate samples.
responsive miRNA switches. Methods for generating stable
cell lines typically rely on random integration of the gene
of interest or transduction with viruses. However, random
integration of genetic constructs into the genome is inef-
ficient, nonspecific, and often yields inconsistent levels of
gene expression due to genomic position effects (49). In or-
der to accurately compare the regulatory activities of vari-
ousmiRNA switches, it was imperative that the genetic con-
structs are stably expressed at similar levels to minimize any
biological discrepancies. Therefore, we generated a clonal
CTLL-2 platform line for site-specific integration (Supple-
mentary Figure S5A).We also encoded a tetracycline trans-
activator (tTA2) in the genome of the CTLL-2 platform
line to enable conditional expression of the integrated ge-
netic construct. We verified that gene expression at the inte-
grated loci was robust, consistent, durable, and controllable
by doxycycline (Supplementary Figure S5B and S5C). This
method of targeted integration obviates the complications
from transgene copy variation and genomic position, thus
enabling more accurate comparison of the activities of dif-
ferent regulatory elements such as miRNA switches.
We generated clonal CTLL-2 cell lines that harbored var-
ious miRNA switches encoded in the 3’ UTR of a GFP
reporter (Figure 2A). The constructs were site-specifically
integrated into the genome to ensure comparable levels of
miRNA expression.We designed constructs with single and
multiple copies of IL-2R- or  c-targetingmiRNAswitches
((nx) or  (nx), where ‘n’ represents switch copy num-
ber). We also assembled co-targeting switch systems ((nx)-
 (nx)) to examine potential synergistic effects of silencing
both receptor subunits.
Examination of cytokine receptor expression by cell sur-
face staining revealed that both (nx) and  (nx) effectively
silenced their respective targets (>90% for IL-2R and
>60% for  c), and that receptor levels could be partially res-
cued by (6R)-FA (Figure 2B and Supplementary Figure S6).
Combinatorial expression of (nx) and  (nx) also silenced
both receptors, demonstrating that co-targeting switch sys-
tems can simultaneously regulate the expression of mul-
tiple endogenous targets. However, multiple-copy miRNA
expression only further reduced cytokine receptor levels by
a small percentage, suggesting that gene silencing via RNAi
Nucleic Acids Research, 2018, Vol. 46, No. 3 1547
may have reached a maximum threshold. We also assayed
for GFP expression as a gauge to estimate the extent of
miRNAmaturation in the presence and absence of drug in-
put. Processing of the primary miRNA by Drosha results
in transcript cleavage and subsequent mRNA degradation,
resulting in reduced translation of the gene (GFP) encoded
in the miRNA construct. We observed a proportional de-
crease in GFP expression with increasing miRNA switch
copies, and GFP expression was elevated in the presence of
(6R)-FA, thus correlating well with the downstream gene-
silencing activities (Supplementary Figure S7).
IL-2R- and c-targeting miRNA switches exhibit tunable
inhibition of T cell proliferation
To examine effects on cell phenotype, we treated clonal cells
harboring various miRNA switch systems with (6R)-FA
and monitored growth in the presence of IL-2 over a 12-
day period. We selected 12 days for the time course of the
experiment because CTLL-2 cells double every∼30 h, so 12
days approximately equal 10 cell doublings. Phenotypic re-
sponses, such as cell growth, are often delayed compared
to changes in gene expression and thus require multiple
cell doublings to exhibit a notable response. We incremen-
tally titrated GFP-miRNA expression via a tetracycline-
repressible promoter to determine the complete phenotypic
response of the cells at different miRNA expression levels
(Figure 3A). When expression was suppressed, all cell lines
exhibited normal growth. However, when miRNA expres-
sion was gradually increased, we observed unique pheno-
types of growth inhibition for each cell line, and systems
with higher miRNA switch copies rendered greater repres-
sion of cell growth. In contrast, a structurally identical, non-
targeting miRNA switch (nt miR) did not produce specific
growth-inhibitory effects, but cell proliferation was slightly
reduced by∼20% at high GFP-miRNA expression possibly
due to increased energetic demands from constitutive pro-
tein expression.
Following the same experimental setup as described
above, we performed time course studies at full miRNA ex-
pression (no doxycycline) and observed effective inhibition
of cell proliferation by both(nx) and  (nx), but cell growth
was rescued by (6R)-FA (Figure 3B and SupplementaryFig-
ure S8A). Systems harboring a single miRNA switch ex-
hibited up to a 7-fold increase in growth in the presence of
(6R)-FA. However, multiple-copy switch systems rendered
stronger repression of cell growth, resulting in up to 100-
fold regulatory dynamic range (fold-change in cell count
between the presence and absence of (6R)-FA). Surpris-
ingly,  (3x) was not more potent than  (2x) at repressing
cell growth, suggesting a point of diminishing return with
>2 copies of this particular  c-targeting miRNA sequence.
Combinatorial expression of (1x)- (1x) exhibited a 5-
fold higher regulatory dynamic range than either miRNA
switch alone, indicating that the gene-silencing activities of
each miRNA were maintained and non-redundant. Quan-
tification of the growth response indicates that combina-
torial targeting of multiple cytokine receptors rendered
greater changes in cell doubling time (DT), with up to a 5-
fold change in DT between untreated and (6R)-FA-treated
cell populations (Supplementary Figure S8B). Although
multiple-copy switch systems only marginally reduced IL-
2R and  c receptor expression, the phenotypic results in-
dicate that small changes in cytokine receptor expression
may exhibit potent downstream regulatory responses.
To examine the specificity of the regulatory response,
we treated clonal cells harboring (2x) with either (6S)-
or (6R)-FA and monitored growth over time (Figure 3C).
We selected (2x) as a representative switch system to il-
lustrate the contrast in response––cells treated with (6R)-
FA displayed a >100-fold increase in cell count after 12
days of growth compared to the untreated population,
whereas cells treated with (6S)-FA did not exhibit a signif-
icant growth response. Assessment of GFP expression lev-
els further supported the observed downstream phenotypic
responses––GFP expression was elevated only in the pres-
ence of (6R)-FA.
miRNA switch systems exhibit dynamic control over au-
tonomous T cell growth
Therapeutic applications will require genetic control sys-
tems that are dynamic and capable of responding in near
real time to input signals. To investigate whether the
miRNA switch systems react dynamically to changes in
drug input levels, we monitored the growth of cells in re-
sponse to the addition and withdrawal of (6R)-FA. At the
beginning of the experiment (day 0), miRNA expression
was induced and each cell line was split into two volumes, to
which (6R)-FA was added to one. The cell lines were main-
tained in one condition (with or without (6R)-FA) for 12
days followed by another 12 days in the reverse condition
(without or with (6R)-FA). Since CTLL-2 cells are depen-
dent on exogenous cytokine, cell growth over long periods
may be sensitive to the timing and levels of IL-2 supple-
mented to the culture medium. Therefore, we stably inte-
grated a proliferative cytokine (IL-15) along with the indi-
vidual miRNA switch systems into the CTLL-2 platform
line to support autonomous cell division without exoge-
nous cytokine input (Figure 4A and Supplementary Figure
S9). This strategy ensured that the observed phenotypic re-
sponses were entirely due to (6R)-FA-mediated regulation
of cytokine receptor expression.
Results indicate that T cell proliferation was dynamically
regulated, displaying up to 4-fold higher growth after (6R)-
FA addition and up to 26-fold diminished growth following
(6R)-FA removal (Figure 4B). Cells harboring the (2x)-
 (2x) system showed stronger repression of cell growth and
a greater response to changes in drug availability compared
to those expressing the (1x)- (1x) system. However, the
stronger inhibition in the absence of drug input also resulted
in a relatively longer recovery phase, indicating that the cells
may require a longer exposure to drug in order to gener-
ate an effective growth response. Assessment of GFP ex-
pression shows that transcript levels also correlated dynam-
ically with (6R)-FA treatment (Supplementary Figure S10).
In contrast, cells expressing a non-targeting miRNA switch
(nt miR) did not exhibit significant changes in growth.
DISCUSSION
Synthetic biological systems have vast potential in health
and medical applications. In particular, cell-based thera-
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Figure 3. IL-2R- and  c-targeting miRNA switches exhibit tunable inhibition of T cell proliferation. (A) Complete regulatory response of cell growth at
various miRNA expression levels. Clonal cell lines harboring miRNA switch systems targeting IL-2R and/or  c were treated with the specified concen-
trations of (6R)-FA for five days, and GFP-miRNA expression was titrated via a tet-repressible promoter. ‘nt miR’, non-targeting miRNA switch. (B) T
cell proliferation response mediated by (6R)-FA-responsive miRNA switch systems. Clonal cell lines in (A) at full miRNA expression were treated with the
specified concentrations of (6R)-FA for 12 days. See Supplementary Figure S8A for individual growth curves. Italicized numbers (red) indicate fold-change
in cell count between 0 and 250 M (6R)-FA. (C) Effects of (6S)-FA and (6R)-FA on T cell proliferation and GFP expression. A clonal cell line harboring
(2x) was treated with the specified concentrations of (6S)-FA and (6R)-FA for 12 days. Cell count and GFP mean fluorescence intensity (MFI) were
measured via flow cytometry, and GFPMFI was normalized to those of cells harboring nt miR. Reported measurements represent mean ± SD from three
replicate samples. n = 3; **P < 0.01. Two-tailed P values were calculated with Student’s t-test.
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Figure 4. Multi-targeted miRNA switch systems enable dynamic control of autonomous T cell growth. (A) Schematic representation of the miRNA switch
system stably integrated in autonomously dividing CTLL-2 cells. The miRNA switches target endogenously expressed IL-2R and/or  c, which form part
of the heterotrimeric IL-15 receptor. Clonal cell lines also expressed a transgene encoding a cell surface marker (CD19) and proliferative cytokine (IL-15).
Stably integrated cells were selected by gating for GFP+CD19+ cells (see Supplementary Figure S9). Blue, aptamer; black, miRNA; ‘x’, miRNA switch
copy number; IL-15R, IL-15 receptor. (B) Dynamic control of autonomous T cell growth. Clonal cell lines harboring the indicated miRNA switch systems
were treated with or without (6R)-FA for 12 days. On day 12, the cell lines were reseeded and split into two equal volumes, to which (6R)-FA was added
to one. Growth was monitored for an additional 12 days. The cell lines were grown in the absence of exogenously fed cytokine. Cell count measurements
represent mean ± SD from three replicate samples. Italicized numbers (red) indicate fold-change in cell count on day 24. n = 3; **P < 0.01. Two-tailed P
values were calculated with Student’s t-test.
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pies, which are quickly emerging as the next-generation
therapeutic, represent prime indications for cellular repro-
gramming. Cells have inherent biological advantages and
unique functionalities that may be harnessed to treat dis-
eases that have thus far eluded effective treatment. How-
ever, the complexity and therapeutic potency of engineered
cells also present challenges and safety concerns that must
be addressed. Recent efforts in the field of mammalian syn-
thetic biology have focused on tackling these issues by en-
coding novel regulatory systems that interface with endoge-
nous signaling pathways to modulate biological function
or cell behavior (50–52). However, in general there are lim-
ited gene-regulatory systems that are suitable for broad ap-
plication in clinical settings. Synthetic inducible promoter
systems are used extensively in research, but they rely on
transcriptional regulatory proteins that are heterologous in
nature and unsuitable for stable expression in physiological
conditions. Most of the chemical inducers are also too toxic
to administer at sufficiently high concentrations in human
subjects.
In this work, we developed a synthetic, drug-responsive
miRNA-based regulatory system that has broad utility in
biological systems that require genetic control. Through ra-
tional design and structural engineering, we constructed
miRNA switches that are controllable by (6R)-FA, the bi-
ologically inactive ingredient of the pharmaceutical drug
leucovorin. Unlike other commonly used small-molecule
drugs (e.g., theophylline), (6R)-FA exhibits no observable
toxicity to the cell line at concentrations used for regulating
RNA switch activity, thus permitting safe and prolonged
administration in translational applications. Importantly,
the miRNA switches exhibit high specificity to (6R)-FA and
avoid potential nonspecific activation by structurally simi-
lar molecules.We pursued a design strategy to target critical
upstream signaling components (IL-2R and  c) in the T
cell proliferation pathway, thereby using natural amplifica-
tion cascades to generate enhanced downstream functional
responses.
The miRNA control systems, each encoding a different
combination and/or switch copy, produced unique func-
tional responses and regulatory dynamic ranges. Combina-
torial targeting of IL-2R and  c exhibited a greater re-
pression of cell growth than targeting either receptor alone,
highlighting the synergistic potential of silencing multiple
endogenous genes. The co-targeting switch systems also
functioned dynamically in response to changes in (6R)-
FA availability, exerting both positive and negative regula-
tion of autonomous cell growth following the addition and
withdrawal of (6R)-FA, respectively. The growth response
to (6R)-FA addition was weaker than that for drug with-
drawal, likely due to the delay inmiRNAdegradation. Stud-
ies have shown that mature miRNAs in mammalian cells
can exhibit half-lives of greater than 24 h (53), thus pro-
longing their gene-silencing effects even after their matura-
tion is halted. Therefore, we would expect the addition of
(6R)-FA to gradually (rather than immediately) reverse the
inhibitory effects on cell growth. Nevertheless, the cells were
able to expand from a dormant state given sufficient time.
In contrast to suicide switches where cells are irreversibly
eliminated in an all-or-none approach, the miRNA control
systems enable tunable regulation of T cell growth, which
may be advantageous in preserving T cell effector function.
The miRNA switches described in this work are also ver-
satile and may be applied to control the expression of other
endogenous genes. For example, checkpoint inhibitory re-
ceptors (e.g. CTLA-4) play major roles in modulating the
activation of physiological immune responses from T cells
and thus represent prime targets for regulation (54). The
targeting sequence in the miRNA hairpin can be readily al-
tered to change the target of interest without affecting the
switch’s responsiveness to (6R)-FA. To createmore sophisti-
cated control systems, synthetic miRNA clusters may be as-
sembled to simultaneously regulate multiple signaling path-
ways. The development of RNA aptamers to other small
molecules may also facilitate the construction of more ad-
vanced RNA-based control systems, where additional in-
puts are used to implement layers of regulation. However,
the field is limited by the lack of available aptamers that
sense clinically suitable drugs. Advancements in aptamer se-
lection, such as the incorporation of high-throughput tech-
nologies (i.e. next-generation sequencing), will facilitate the
generation of new aptamers to clinically-relevant targets
(55,56).
Based on the measured binding affinity of the aptamer,
the effective doses of (6R)-FA required to trigger a full re-
sponse from the switch was higher than anticipated. This
discrepancy is likely due to a lowered intracellular concen-
tration of the drug. Since (6R)-FA is an unnatural isomer of
folinic acid, it may not be as readily transported into cells as
compared to the natural 6S isomer (57). Therefore, the ac-
tual concentration of (6R)-FA that is available for binding
to the miRNA switch is likely lower than the concentration
dissolved in the cell culture medium. The concentrations of
(6R)-FA used in this study (50–500 M) were also gener-
ally higher than the reported steady-state serum concen-
trations of (6R)-FA (∼20–100 M) (42,57). However, the
miRNA switch systems exhibited responses at concentra-
tions as low as 50 M, and combinatorial targeting of mul-
tiple cytokine receptors enhanced the regulatory dynamic
range of cell growth. To improve the robustness of the sys-
tem, miRNA switches may be applied to regulate multiple
key targets within a signaling pathway. Alternatively, the in-
dividual miRNA switch may be improved by screening a li-
brary of mutations in the miRNA basal segments to iden-
tify new switch designs that exhibit greater silencing of tar-
get gene. miRNA switch designs that are better substrates
for Drosha processing and that maintain high affinity for
(6R)-FAmay achieve enhanced gene-regulatory activities at
lower concentrations of (6R)-FA.
Although still in its infancy, mammalian synthetic bi-
ology is already inspiring the design and development of
next-generation therapeutics (22,31–34). Along with new
technologies in genome editing and biomarker discovery
(58,59), synthetic regulatory systems and genetic circuitries
support the design of engineered cells that have higher speci-
ficity, increased potency, and diversified functional outputs.
Furthermore, the evolving tool kit of cell engineering will
enable researchers to build more advanced cell therapy plat-
forms by incorporating novel modes of regulation, such as
exogenous control of therapeutic output and dosage, to gen-
erate versatile and safer therapeutics. The recent progress in
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the field highlights the potential of using synthetically engi-
neered biological systems in advancingmedical innovations.
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